drugset
drugset / Trial / NCT06671938

Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson's Disease and Patients With Multiple System Atrophy

NCT06671938 ↗

Phase 2 Active not recruiting 38 enrolled BioArctic AB Worldwide Clinical Trials · collab
RandomizedSequentialQuadruple-blindTreatment

Summary

The primary objective of this study is to assess the safety and tolerability of exidavnemab after multiple dosing versus placebo.

Timeline

Start
2024-10-24
Primary completion
2026-08-17
Completion
2026-08-17

Drugs

EvaluationDrugModalityDoseRoute
Subject exidavnemab Unknown — Intravenous

Indications

Parkinson disease multiple system atrophy